<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326946</url>
  </required_header>
  <id_info>
    <org_study_id>2019-AAR-012</org_study_id>
    <nct_id>NCT04326946</nct_id>
  </id_info>
  <brief_title>International Alfapump Cohort Study</brief_title>
  <acronym>TOPMOST</acronym>
  <official_title>International Alfapump Cohort Study: in Patients With Refractory Ascites Due to Liver Cirrhosis or Malignant Ascites With a Life Expectancy of 6 Months or Less</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequana Medical N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequana Medical N.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Registry is designed to follow patients who have been implanted with an alfapump system,
      which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a real-world setting, all patients implanted with an alfapump system according to it's
      intended use, not participating in another clinical study in which the alfapump is studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Patient survival at 6 months post implant</measure>
    <time_frame>6 months post-implant</time_frame>
    <description>The primary outcome will be patient survival with a functional alfapump system at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess occurrence of (major) reportable events.</measure>
    <time_frame>2 years</time_frame>
    <description>Reportable events are defined as any events per the definition in 9.1 and classified as renal event, variceal bleeding, hepatic encephalopathy an infection or assessed as related (not classified &quot;improbable related&quot; or &quot;cannot be attributed&quot; per the definitions below) to; the implant procedure, device or therapy by the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess safety at 1-month post implant for procedure related incidents.</measure>
    <time_frame>1 month post implant</time_frame>
    <description>o Occurrence of adverse events considered related to implant, product or therapy by the treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical impact on liver and renal function in liver &amp; renal blood lab panel</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical impact as assessed by changes in Prealbumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical impact on liver and renal function in liver &amp; renal blood lab panel</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical impact as assessed by changes in Albumin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical impact on liver and renal function in liver &amp; renal blood lab panel</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical impact as assessed by changes in eGFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical impact on liver and renal function in liver &amp; renal blood lab panel</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical impact as assessed by changes in createnine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Ascites Questionnaire (pre implant &amp; at each visit after the first month post implant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>SF-36 (pre implant at each visit after the first month post implant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life on patient activity</measure>
    <time_frame>4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant</time_frame>
    <description>Assess change in physical activity pre- and post implant To assess daily activity and stress level of patients for up to 48 weeks following implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life on patient activity</measure>
    <time_frame>4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant</time_frame>
    <description>Assess change in physical activity pre- and post implant To assess and evaluate sleep of patients for up to 48 weeks following implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life on patient activity</measure>
    <time_frame>4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant</time_frame>
    <description>Assess change in physical activity pre- and post implant
To assess daily activity and stress level of patients for up to 48 weeks following implant
To assess and evaluate sleep of patients for up to 48 weeks following implant
To assess patient's abdominal pain/discomfort, appetite, satiety, and tiredness
To assess objective stress and inflammation parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life on patient activity</measure>
    <time_frame>4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant</time_frame>
    <description>Assess change in physical activity pre- and post implant To assess patient's abdominal pain/discomfort, appetite, satiety, and tiredness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the alfapump on ascites symptoms related quality of life on patient activity</measure>
    <time_frame>4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant</time_frame>
    <description>Assess change in physical activity pre- and post implant To assess objective stress and inflammation parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical impact on ECOG</measure>
    <time_frame>2 years</time_frame>
    <description>change in ECOG performance scale pre- and post implant</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Liver Cirrhoses</condition>
  <condition>Malignant Ascites</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alfapump</intervention_name>
    <description>alfapump implementation</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biobanking of urine, ascites and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The TOPMOST will target to include, in a real-world setting, all patients implanted with an
        alfapump system as per intended use, not participating in another clinical study in which
        the alfapump is being evaluated.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients implanted with an alfapump are eligible for this registry

        Exclusion Criteria:

          -  Patients younger than 18 years

          -  Pregnancy

          -  Inability to operate the Smart Charger to recharge the alfapump

          -  Participating in another study in which the alfapump is studied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Gottardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Capel, MSc</last_name>
    <phone>+41-44-4035512</phone>
    <email>jeroen.capel@sequanamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gijs Klarenbeek, MD</last_name>
    <phone>+41-44-4035597</phone>
    <email>gijs.klarenbeek@sequanamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universit√§tsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Berg, Prof. Dr.</last_name>
      <phone>0341 / 97-12330</phone>
      <email>Thomas.Berg@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Berg, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea De Gottardi, Privatdozent</last_name>
      <phone>0041316323570</phone>
      <email>andrea.degottardi@ikp.unibe.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

